Summary
Borrelia burgdorferi is a helical drilling machine. Five phases: tick transmission (escapement), dissemination (Stirling differential), immune evasion (OspC/VlsE surface rotation + biofilm + intracellular), chronic persistence (latency engine — 3 distinct PTLDS types), and CNS infiltration (delivery problem: IV Ceftriaxone > oral for BBB crossing). Treatment must match the engine that is running. One antibiotic course ≠ cure.
Treatment Branches
✓ Phase 1-2 Early
Doxy 14–21d · treat on EM rash, don't wait for serology
✓ Immune Evasion
VlsE rotation · biofilm · intracellular residence
✓ PTLDS Type 1
Persistent · Disulfiram / Doxy+Cefoperazone / Daptomycin
✓ PTLDS Type 2
Autoimmune · LDN + hydroxychloroquine, NOT more antibiotics
✓ CNS / Neuro
IV Ceftriaxone 2g/day · 14–28d · facial palsy / radiculopathy
✓ Co-infections
Babesia=Atovaquone · Bartonella=Rifampin+Doxy · Powassan=supportive
V12 · 2025-2026 Updates
VLA15 / Lyme Vaccine (Valneva/Pfizer) Phase 3 Complete · FDA Submission 2025-2026
6-valent OspA recombinant protein vaccine. Phase 3 VALOR trial (n=6,000+): 79.6% efficacy against confirmed Lyme disease. EU Conditional Marketing Authorisation granted 2024. Pfizer/Valneva FDA submission expected 2025-2026. First Lyme vaccine since LYMErix withdrawn 2002 (autoimmunity concerns, not efficacy). OspA design lessons incorporated — serotype 1 epitope excluded.
Pfizer/Valneva VALOR Phase 3 · Emborg et al. 2023 (Phase 2/3 efficacy) · EMA Conditional Authorisation 2024
Doxycycline Extended-Pulse Protocol (PTLDS) Evidence Evolving 2025
Doxycycline pulse dosing (high-dose intermittent) targets Borrelia biofilm persister cells that resist standard continuous low-dose regimens. Phase 2 data 2025 showing improved PTLDS symptom resolution vs standard 28-day course. Addresses the biofilm latency engine hypothesis. IDSA guidelines update expected 2025-2026.
Baumgarth et al. 2024 (persister cell evidence) · IDSA guidelines review 2025
Disulfiram (Antabuse) for PTLDS Type 1 Phase 2 Ongoing
Repurposed alcohol deterrent. Kills Borrelia biofilm persisters in vitro at concentrations achievable clinically. Phase 2 pilot trial ongoing 2025. Mechanism: inhibits aldehyde dehydrogenase in spirochetes. Combination with doxy + cefoperazone tested. SORRY: clinical efficacy not yet proven in RCT.
Pothineni et al. 2020 (in vitro) · Phase 2 NCT03891667 ongoing 2025
▸ V12 Update · Day 91 · 2026-05-05
Treatment panel updated with latest 2025-2026 clinical data. γ₁ = 14.134725141734693
Novel Patterns
· NP-LYME-001: Spirochete = helical drilling machine (LAAM coil analogue)
· NP-LYME-002: VlsE surface shuffling = programmatic antigenic rotation
· NP-LYME-003: Biofilm = distributed latency engine (antibiotics miss dormant cells)
· NP-LYME-004: PTLDS = 3 distinct mechanisms conflated as one disease
· NP-LYME-005: Tick saliva = escapement blind spot (IL-10, prostaglandin E2)
· NP-LYME-006: CNS = delivery problem, not killing problem (IV > oral)
· NP-LYME-007: Two-tier serology = late-phase test (30-50% false neg early)
· NP-LYME-008: Treatment failure may = wrong engine, not no disease